Savolitinib is a domestically innovative drug independently developed by a Chinese pharmaceutical enterprise. Developed by Hutchmed, it was approved for marketing in China in 2021. It is mainly indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations, and belongs to the class of small-molecule targeted drugs.
Detailed Description
1. Drug Attributes
Savolitinib is China's first approved MET inhibitor. Led and developed by a domestic R&D team, it is classified as a Class 1 innovative chemical drug in China with complete independent intellectual property rights. Its R&D and launch mark a significant breakthrough in the field of targeted lung cancer therapy in China.
2. Indications and Mechanism of Action
By inhibiting the abnormal activation of MET protein, this drug blocks the tumor cell growth signaling pathway. It is indicated for patients confirmed to have MET exon 14 skipping mutations through testing. Such mutations account for approximately 3%-4% of non-small cell lung cancers and are relatively rare driver gene alterations.
3. R&D Background and Collaboration
Although Savolitinib is a domestically produced drug, its clinical trial phase involved collaboration with the multinational pharmaceutical company AstraZeneca to conduct international multicenter studies. These studies aim to expand the indication scope and verify the efficacy of the drug. This collaboration model is common in the global layout of innovative drugs, yet the ownership of drug rights remains primarily with the domestic enterprise.
4. Precautions for Use
Savolitinib is a prescription drug and must be used strictly in accordance with the doctor's instructions, based on the results of genetic testing.
Common adverse reactions include edema, nausea, and abnormal liver function. Regular monitoring is required, and the medication regimen should be adjusted promptly when necessary.
Patients shall not purchase the drug or adjust the dosage without authorization. Before medication, relevant examinations should be completed and the physical condition should be evaluated comprehensively.
If patients meet the indications, it is recommended that they visit the department of oncology or respiratory medicine in a regular hospital. The mutation type should be clarified through pathological testing and genetic screening, after which a specialist physician will formulate an individualized treatment plan.
